Global Multidisciplinary Cardiometabolic Care Delivery: A Blueprint for Success From UNITE.

Mortality and morbidity from cardiovascular disease continue to rise along with obesity and other cardiometabolic risk factors, making comprehensive management for cardiometabolic disease (CMD) imperative. Despite available treatments, gaps exist in CMD care. Revolutionizing the Delivery of Care in CV Disease and T2DM: The Pilot Cardiometabolic Clinic Initiative (UNITE) is a global initiative aimed at improving outcomes of cardiovascular disease risk in patients with type 2 diabetes mellitus.

Cardiomyocyte and stromal cell cross-talk influences the pathogenesis of arrhythmogenic cardiomyopathy: a multi-level analysis uncovers DLK1-NOTCH pathway role in fibro-adipose remodelling.

Arrhythmogenic Cardiomyopathy (ACM) is a life-threatening, genetically determined disease primarily caused by mutations in desmosomal genes, such as PKP2. Currently, there is no etiological therapy for ACM due to its complex and not fully elucidated pathogenesis. Various cardiac cell types affected by the genetic mutation, such as cardiomyocytes (CM) and cardiac mesenchymal stromal cells (cMSC), individually contribute to the ACM phenotype, driving functional abnormalities and fibro-fatty substitution, respectively.

Anatomical-guided third-generation laser balloon ablation for the treatment of paroxysmal atrial fibrillation assessed by continuous rhythm monitoring: results from a multicentre prospective study.

Aims: The third-generation laser balloon (LB3) is an established ablation device for pulmonary vein isolation (PVI) that allows direct visualization of the anatomical target. Equipped with an automatic circumferential laser delivery modality, it aims at continuous circumferential PVI, improving both acute and clinical outcomes. We sought to evaluate the clinical efficacy of LB3 ablation using an anatomical-based approach without verifying electrical isolation.